Duaa Jaafar Jaber Al-Tamimi, Mustafa Ihssan Abbas Al-Mahroos, Mariam Jaafar Jaber Al-Tamimi, Jaafar Jaber Ibraheem
email@example.com , firstname.lastname@example.org
Duaa Jaafar Jaber Al-Tamimi1, Mustafa Ihssan Abbas Al-Mahroos2, Mariam Jaafar Jaber Al-Tamimi3, Jaafar Jaber Ibraheem3*
1Department of Pharmacy, Al-Nisour University College, Ministry of Higher Education and Scientific Research, Baghdad, Iraq.
2College of Pharmacy, Alfarahidi University, Ministry of Higher Education and Scientific Research, Baghdad, Iraq.
3Department of Pharmacy, Al-Manara College for Medical Sciences, Ministry of Higher Education and Scientific Research, Missan, Amarah, Iraq.
Volume - 15,
Issue - 5,
Year - 2022
Cefuroxime axetil (CA) is a broad-spectrum second-generation cephalosporin antibiotic resistant to beta-lactamase used for treating different kinds of infections. This study was conducted to compare the pharmacokinetics (PK) and to evaluate the bioequivalence (BE) between a newly formulated generic CA 500mg tablets as a test formula with the same dose of the brand formula as the reference product applying 2-way, 2-treatment, 2-period, 2-sequence, randomized crossover design with six days washout interval between dosing. After overnight fasting for 12 hours, both CA products were administered to 28 healthy male adult Arabic subjects, followed by serial blood samples obtained from each subject before drug dosing (0-hr) and then up to 8 hours post-dosing. The calculated PK parameters Cmax, Tmax, AUC0–t, AUC0–8, Thalf, MRT, Cl and Vd obtained from each product were statistically compared by ANOVA and 90% confidence interval tests to evaluate the BE between both products. Based on international guidance on bioequivalences like FDA and EMEA, it was concluded from this research that the test and the reference formulas are bioequivalent since the 90% confidence intervals were within the accepted ranges of 80.00-125.00%. All participants tolerated both products well, and they were discharged without any significant alterations in their clinical baseline characteristics. Therefore, the newly formulated generic CA 500mg tablets may be prescribed in clinical practice and used as a safe and effective alternative to the brand product.
Cite this article:
Duaa Jaafar Jaber Al-Tamimi, Mustafa Ihssan Abbas Al-Mahroos, Mariam Jaafar Jaber Al-Tamimi, Jaafar Jaber Ibraheem. Pharmacokinetic Comparison and Bioequivalence Evaluation between a Newly Formulated Generic and the Brand Cefuroxime Axetil Tablets in Healthy Male Adult Fasting Subjects. Research Journal of Pharmacy and Technology. 2022; 15(5):2184-2. doi: 10.52711/0974-360X.2022.00363
Duaa Jaafar Jaber Al-Tamimi, Mustafa Ihssan Abbas Al-Mahroos, Mariam Jaafar Jaber Al-Tamimi, Jaafar Jaber Ibraheem. Pharmacokinetic Comparison and Bioequivalence Evaluation between a Newly Formulated Generic and the Brand Cefuroxime Axetil Tablets in Healthy Male Adult Fasting Subjects. Research Journal of Pharmacy and Technology. 2022; 15(5):2184-2. doi: 10.52711/0974-360X.2022.00363 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-5-45
1. PrCeftin product monograph, GlaxoSmithKline Inc., 7333 Mississauga Road, Mississauga, Ontario, L5N 6L4, Control Number: 234485, Date of Revision: May 5, 2020.
2. Zinnat product information, GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, Date of revision of the text: November 2019.
3. Sara T , Klaus SJ , Ninna BN, Martin S , Dennis SH , Kai HWL , et al . Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers. J Med Microbiol. 2020;69(3):387-395.
4. Iyad NM, Muhammad HS, Rabia IY, Muhammad H, Sabahat J, Tariq A. Formulation Development and Optimization of Cefuroxime Axetil tablets by Direct Compression Method and its Stability Studies. Lat Am J Pharm. 2012;31(2):271-278.
5. Fozia I , Zafar AM , Fouzia H, Syed MFH, Sabahat J, Shazia N, et al. Formulation design and evaluation of Cefuroxime axetil 125 mg immediate release tablets using different concentration of sodium lauryl sulphate as solubility enhancer. Brazi J of Pharm Sci. 2014;50(4):943-953.
6. Jammula S, Chinam NP, Suryakanta S, Kanhu CP, Allupati PP, Sarwar B. Improvement in the dissolution rate and tableting properties of cefuroxime axetil by melt-granulated dispersion and surface adsorption. Acta Pharm. Sin. B. 2013;3(2):113122.
7. Swapna R, Basava R, Shailaja P. Formulation in vitro and in vivo evaluation of cefuroxime axetil floating tablets using natural gums. Int. J. Life Sci. Pharma Res. 2019; 9(1):37-53.
8. Al-Tamimi DJ, Hussein AA. Formulation and Characterization of Self-Microemulsifying Drug Delivery System of Tacrolimus. Iraqi J Pharm Sci. 2021;30(1):91-100.
9. Al-Tamimi DJ, Hussein AA. Preparation and In-vitro Characterization of Tacrolimus as a Solid Self-microemulsion. IJDDT. 2021;11(1):70-78.
10. Finn A , Straughn A, Meyer M , Chubb J . Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos. 1987;8(6):519-526.
11. Chen RR , Lee TY , Hsieh WC. Effect of food on pharmacokinetics of cefuroxime axetil in Chinese subjects. J Formos Med Assoc. 1992 Dec;91(12):1177-1181.
12. Ying W, Lin F, Cheng Y, Huang K, Hongwei F. Diet-induced Alterations in Pharmacokinetics of Cefuroxime Axetil in Healthy Chinese Subjects. Indian J Pharm Sci 2019;81(5):966-970.
13. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. U.S. Department of Health and Human Services, FDA, Centre for Drug Evaluation and Research (CDER), Revision 1, 2003.
14. Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. U.S. Department of Health and Human Services, FDA, Centre for Drug Evaluation and Research (CDER). Draft Guidance, 2013.
15. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs-General Considerations, U.S. Department of Health and Human Services, FDA, Centre for Drug Evaluation and Research (CDER). Draft Guidance, 2014.
16. European Medicines Agency (EMEA): Committee For Medicinal Products For Human Use (CHMP). Guidelines On The Investigation of Bioequivalence, London, UK, 2010.
17. Henrike P. Generic drug workshop: current EMA regulatory perspectives on bioequivalence study and biowaiver. Federal Institute for Drugs and Medical Devices. Seoul, December 2017.
18. Casimir AA, Amine C, Yahia C, Mustapha B, Jean MC. Bioequivalence regulation in emerging countries: example of Moroccan regulations on immediate release formulations and comparison with international guidelines. J Appl Pharm Sci. 2019;9(11):28-35.
19. Elambharathy E. Guidelines Requirements for Orally Administered Generics (IR Products) in Gulf Cooperation Council Countries, European Union and United States of America. J Bioequiv Availab. 2019; 11:6-13.
20. Alani ME, Al-Tamimi DJ, Al-Mahroos MI, Ammoo1 AM, Al-Tamim MJ, Ibraheem JJ. Bioequivalence Study of a Newly Developed Azithromycin Suspension Versus Zithromax® Following a Single Dose to Healthy Fasting Adult Subjects. IJDD. 2021;11(1):159-165.
21. Jabbar EG, Al-Tamimi DJ, Al-Mahroos MI, Al-Tamimi ZJ, Ibraheem JJ. Pharmacokinetics and bioequivalence study of two formulations of Cefixime Suspension. J Adv Pharm Edu Res. 2021;11(1):170-177.
22. Al-Mahroos MI, Al-Tamimi DJ, Al-Tamimi ZJ, Ibraheem JJ. Clinical pharmacokinetics and bioavailability study between generic and branded fluconazole capsules. J Adv Pharm Edu Res. 2021;11(1):161-169.
23. Afaq Mahde Ammoo, Duaa Jaafar Jaber Al-Tamimi, Mustafa Ihssan Abbas Al-Mahroos, Mariam Jaafar Jaber Al-Tamimi, Jaafar Jaber Ibraheem. Pharmacokinetics of Fluconazole Tablets Administered to Healthy Subjects. J Adv Pharm Edu Res. 2021;11(2):92-99.
24. Al-Tamimi DJ, Ammoo AM, Alani ME, Ibraheem JJ. Pharmacokinetics and Dose Proportionality of Betahistine in Healthy Individuals. Sci Pharm. 2020;88(13):1-8.
25. Al-Tamimi DJ., Alani ME., Ammoo AM., Ibraheem JJ. Linear pharmacokinetics of doxazosin in healthy subjects. Int J Res Pharm. Sci.2020;11(1):1031-1039.
26. Abass HM, Al-Tamimi KF, Al-Tamimi DJ, Ibraheem JJ. Correlation between Cyclosporine Blood Levels and Area under Blood Concentration Time Curve in Iraqi Bone Marrow Transplant Patients Treated with Neoral® Oral Solution. Sci Pharm. 2020;88(8):1-12.
27. Al-Tamimi DJ, Maraie NK, Arafat T. Comparative bioavailability (bioequivalence) study for fixed dose combination tablet containing amlodipine, valsartan and hydrochlorothiazide using a newly developed HPLC-MS/MS method. Int J Pharm Pharm Sci. 2016;8(7):296-305.
28. Sung KC, Changchein Y-C, Chen P-C, Lu C-L, Han R-Y, Lin YY. Relative bioavailability study of cefuroxime axetil tablets. J Food Drug Anal. 1999;7(1):45-52.
29. Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, Al-Bella S, et al. Bioequivalence evaluation of two brands of cefuroxime 500 mg tablets (Cefuzime and Zinnat) in healthy human volunteers. Biopharm Drug Dispos. 2000 Sep;21(6):205-210.
30. Asiri YA, Al-Hadiya BM, Kadi AA, Al-Khamis KI, Mowafy HA, El-Sayed YM. Comparative bioavailability study of cefuroxime axetil (equivalent to 500 mg cefuroxime/tablet) tablets (Zednad® versus Zinnat®) in healthy male volunteers. Int J Clin Pharmacol Ther. 2011;49(9):571-576.
31. Sabati AMA, Abdalwali AS, Al Hajji MA. study of two brands of cefuroxime 500 mg tablets (Bioxime® and Zinnat® ) in adults healthy volunteers. J Chem and Pharm Res. 2014, 6(6):2823-2829.
32. Pistos C, Michalea S, Kalovidouris M, Kontopoulos G, Georgarakis M . Bioequivalence evaluation of 2 brands of cefuroxime axetil 250 mg tablets in healthy human volunteers. Int J Clin Pharmacol Ther. 2004 Jul;42(7):367-72.
33. Michae K, Andrzej LE, Krystyna S-B, Hanna K, Piotr JR, Piotr G. Bioequivalence study of 500 mg cefuroxime axetil film-coated tablets in healthy volunteers. Acta Pol Pharm. 2012;69(6):1356-1363.
34. Iyad NM, Muhammad HS, Rabia IY. Pharmacokinetic and Bioequivalence Studies of Oral Cefuroxime Axetil 250 mg Tablets in Healthy Human Subjects. J Bioequiv Availab. 2014;6(5):149-152.
35. Rojanasthien N, Boonchaliew C, Kumsorn B, Sangdee C. A bioequivalence study of the cefuroxime axetil in healthy volunteers. J Med Assoc Thai. 2003 Nov;86(11):1063-1072.
36. Choi Y, Jin SE, Lee MK, Kim CK. In vitro dissolution and in vivo bioequivalence evaluation of two brands of cefuroxime axetil tablets. Arzneimittelforschung 2009; 59(1): 42-48
37. Gustavo DM, André B, Ligia V, Anil KP, Simrit R, Tausif M, et al. Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects. Arzneimittelforschung. 2010; 60(2):101-105.
38. Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 1997.
39. Zhang Z. FDA’s Current Practice and Challenges in the Use of Dissolution Similarity Testing for Demonstration of Bioequivalence – Case Studies, Bioequivalence Office of Generic Drugs, CDER, FDA Dissolution Similarity Workshop, May 2019.
40. Ramadan AA, Bakdash M. Direct Spectrophotometric Determination of Cefuroxime Axetil in Pure Form and Pharmaceutical Dosage Forms. JAC. 2018;15(2):6282-6295.
41. Chow, S. C.; Liu, J. P. Design and analysis of bioavailability and bioequivalence Studies. 2.ed.; Marcel Dekker: New York, USA. 2000.
42. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), ICH Harmonized Guidance: Guidance for Good Clinical Practice E6(R2), November 2016.
43. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1), Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), March 2018.
44. WMA Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects, 64th WMA General Assembly, Fortaleza, Brazil, October 2013.
45. Alfeen MA, Yildiz Y. New Development Method for Determination of Cefuroxime Axetil (CUA) and Cefprozil (CZ) in Pharmaceutical Drugs by RP-HPLC. Am J Biomed Sci & Res. 2019;4(1):54-57.
46. Guidance for Industry: US Department for Health & Human Services: Bioanalytical Method Validation for human studies, FDA, Centre for Drug Evaluation and Research (CDER), 2001.
47. Guidance for Industry:US Department for Health & Human Services: Bioanalytical Method Validation for human studies, FDA, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), 2018.
48. Leon S., Andrew BCY, Murray D. Shargel and Yu’s Applied Biopharmaceutics & Pharmacokinetics, 8th ed. McGraw-Hill Education/Medical: New York, NY, USA. 2021.
49. Hartmut D, Stephan S. Rowland and Tozer’s Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 5th ed. LWW: Philadelphia, PA, USA. 2019.
50. Chow SC and Liu JP. Statistical methods for average bioavailability. Design and analysis of bioavailability and bioequivalence Studies, 2ed. Marcel Dekker: New York, USA. 2007, 79-124.
51. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services, FDA, Centre for Drug Evaluation and Research (CDER), 2001.
52. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharmaceutics, 1987; 15: 657–680.
53. Patrick S, Thomas RV. Nonparametric statistical methods in medical research. Anaesth Analg. 2020;131(6):1862-1863.